title: The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain.
abstract: Nesfatin-1 has been demonstrated to possess anti-inflammatory and anti-apoptotic effects in the rat brain with subarachnoid hemorrhage. The study was designed to investigate the influence of nesfatin-1 on inflammatory responses and neuronal cell apoptosis after traumatic brain injury. Wistar rats were subjected to 5, 10 or 20 μg/kg of nesfatin-1 at designed time points (0.5, 2, 4 or 8h after head trauma) intraperitoneally. Rats were sacrificed at hours 2, 6 and 12, as well as day 1, 2, 3 and 5 after head trauma. The administration of 10 or 20 μg/kg of nesfatin-1 at hour 0.5 after head trauma could significantly suppress gene expressions of nuclear factor kappa-B, lessen concentrations of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6, diminish caspase-3 activity as well as reduce number of apoptotic neuronal cells in traumatic rat brain tissues (P<0.05), but the administration of 5 μg/kg of nesfatin-1 not (P>0.05). Moreover, 20 μg/kg nesfatin-1 also significantly suppressed the inflammation and neuronal cell apoptosis when applied 2, 4 or 8h after head trauma. However, a clear concentration-response or time-response relationship was not found. These findings suggest that nesfatin-1 may inhibit nuclear factor kappa-B-dependent inflammatory responses, and lessen caspase-3-mediated neuronal cell apoptosis after traumatic brain injury in rats.
authors.affiliation: Department of Neurosurgery, Cixi People's Hospital, Wenzhou Medical College, Hushan District, Cixi, China.
authors.forename: Chong-Hui
authors.initials: CH
authors.lastname: Tang
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Fu
authors.forename: Xin-Long
authors.initials: XL
authors.lastname: Xu
authors.forename: Xiao-Jie
authors.initials: XJ
authors.lastname: Wei
authors.forename: Hong-Song
authors.initials: HS
authors.lastname: Pan
mesh_terms: D000818:Animals; D017209:Apoptosis; D001930:Brain Injuries / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D002135:Calcium-Binding Proteins / Q000008:administration & dosage / Q000502:physiology*; D053148:Caspase 3 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000008:administration & dosage / Q000502:physiology*; D015870:Gene Expression; D018836:Inflammation Mediators / Q000008:administration & dosage / Q000502:physiology*; D007274:Injections, Intraperitoneal; D008297:Male; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000008:administration & dosage / Q000502:physiology*; D009474:Neurons / Q000502:physiology; D000080866:Nucleobindins; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002135:Calcium-Binding Proteins; D016207:Cytokines; D004268:DNA-Binding Proteins; D018836:Inflammation Mediators; D016328:NF-kappa B; D009419:Nerve Tissue Proteins; C000630652:Nucb1 protein, rat; D000080866:Nucleobindins; C505410:Casp3 protein, rat; D053148:Caspase 3